Prediction and validation of anoikis-related genes in neuropathic pain using machine learning

PLOS ONE, 2025 · DOI: https://doi.org/10.1371/journal.pone.0314773 · Published: February 27, 2025

Simple Explanation

This study explores the role of anoikis-related genes in neuropathic pain (NP), particularly in cases related to lumbar disc herniation (LDH). Neuropathic pain arises from diseases affecting the nervous system. The researchers used machine learning to identify key genes associated with both anoikis and NP. Anoikis is a form of programmed cell death triggered when cells detach from their surroundings. The identified genes were then validated through experiments on rats, confirming their potential as diagnostic markers and therapeutic targets for NP.

Study Duration

Not specified

Participants

Eight patients with LDH-related NP and eight volunteers without NP, and 12 SPF-grade rats

Evidence Level

Not specified

Key Findings

1
Six key anoikis-related genes (HGF, MMP13, ABL1, ELANE, FASN, and LINC00324) were identified as having diagnostic value for NP.
2
These genes are involved in immune-related pathways and biological processes related to genetics and metabolism.
3
Potential therapeutic drugs (valdecoxib, benzocaine, netilmicin, and orphenadrine) were identified for treating LDH-related NP based on their anti-inflammatory and analgesic effects.

Research Summary

This study investigated the role of anoikis-related genes in neuropathic pain (NP), particularly in lumbar disc herniation (LDH). Machine learning algorithms identified six key genes (HGF, MMP13, ABL1, ELANE, FASN, and LINC00324) with diagnostic potential for NP. Experimental validation in rats confirmed the involvement of these genes in NP pathogenesis and suggested potential therapeutic targets and drugs.

Practical Implications

Diagnostic Biomarkers

The identified anoikis-related genes can serve as potential diagnostic biomarkers for neuropathic pain, aiding in early and accurate diagnosis.

Therapeutic Targets

These genes may represent novel therapeutic targets for developing targeted treatments for neuropathic pain.

Drug Repurposing

The identified potential drugs (valdecoxib, benzocaine, netilmicin, and orphenadrine) could be repurposed for treating neuropathic pain, offering new treatment options.

Study Limitations

1
Limited sample size in the GEO database, which may reduce the generalizability of the results.
2
Lack of clinical features of patients, such as age, duration of NP, and comorbidities, in the GEO database.
3
Further validation of potential therapeutic agents is needed through additional in vitro and in vivo experiments.

Your Feedback

Was this summary helpful?

Back to Pain Management